Legacy Wealth Management (Idaho)’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3
Closed -$2.32K 774
2026
Q1
$2.32K Hold
3
﹤0.01% 752
2025
Q4
$2.32K Buy
3
+1
+50% +$679 ﹤0.01% 652
2025
Q3
$1.13K Hold
2
﹤0.01% 609
2025
Q2
$1.05K Sell
2
-1
-33% -$558 ﹤0.01% 590
2025
Q1
$1.9K Sell
3
-15
-83% -$10.3K ﹤0.01% 550
2024
Q4
$12.8K Buy
18
+16
+800% +$13.4K 0.01% 253
2024
Q3
$1.61K Buy
+2
New +$2.23K ﹤0.01% 499

Other funds holding REGN

Legacy Wealth Management (Idaho)'s REGN Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3 shares — an estimated $2.32K sold.

Legacy Wealth Management (Idaho) first reported a position in REGN in Q3 2024 and held it in 7 quarters. The position peaked at $12.8K in Q4 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.32K.
  • Legacy Wealth Management (Idaho) first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Regeneron Pharmaceuticals position peaked at $12.8K in Q4 2024.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.